Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016.

Kjellström B, Nisell M, Kylhammar D, Bartfay SE, Ivarsson B, Rådegran G, Hjalmarsson C.

ERJ Open Res. 2019 Aug 12;5(3). pii: 00075-2019. doi: 10.1183/23120541.00075-2019. eCollection 2019 Jul.

2.

Pulmonary arterial hypertension: assessing risk to improve prognosis.

Kjellström B, Hjalmarsson C, Kylhammar D, Rådegran G.

Expert Rev Cardiovasc Ther. 2019 Jan;17(1):1-2. doi: 10.1080/14779072.2019.1548278. Epub 2018 Nov 15. No abstract available.

PMID:
30422719
3.

Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.

Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, Kjellström B; SveFPH and SPAHR.

Eur Respir J. 2018 May 3;51(5). pii: 1702310. doi: 10.1183/13993003.02310-2017. Print 2018 May.

PMID:
29622568
4.

Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension.

Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Rådegran G.

Scand J Rheumatol. 2018 Jul;47(4):319-324. doi: 10.1080/03009742.2017.1378714. Epub 2018 Mar 12.

PMID:
29528272
5.

Plasma L-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction.

Sandqvist A, Schneede J, Kylhammar D, Henrohn D, Lundgren J, Hedeland M, Bondesson U, Rådegran G, Wikström G.

Heart Vessels. 2018 Mar;33(3):255-263. doi: 10.1007/s00380-017-1055-7. Epub 2017 Oct 3.

6.

[Pulmonary hypertension due to lung diseases].

Kylhammar D, Rådegran G.

Lakartidningen. 2017 Jul 21;114. pii: ELAL. Review. Swedish.

7.

A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.

Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, Wikström G, Rådegran G.

Eur Heart J. 2018 Dec 14;39(47):4175-4181. doi: 10.1093/eurheartj/ehx257.

PMID:
28575277
8.

The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension.

Kylhammar D, Rådegran G.

Acta Physiol (Oxf). 2017 Apr;219(4):728-756. doi: 10.1111/apha.12749. Epub 2016 Jul 31. Review.

PMID:
27381367
9.

P2Y₁ and P2Y₁₂ receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig.

Kylhammar D, Bune LT, Rådegran G.

Eur J Appl Physiol. 2014 Sep;114(9):1995-2006. doi: 10.1007/s00421-014-2921-y. Epub 2014 Jun 15.

PMID:
24929904
10.

Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.

Kylhammar D, Persson L, Hesselstrand R, Rådegran G.

Scand Cardiovasc J. 2014 Aug;48(4):223-33. doi: 10.3109/14017431.2014.931595.

PMID:
24912571
11.

sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.

Lundgren J, Kylhammar D, Hedelin P, Rådegran G.

Acta Physiol (Oxf). 2012 Nov;206(3):178-94. doi: 10.1111/j.1748-1716.2012.02445.x. Epub 2012 Jun 9.

PMID:
22682645
12.

Cyclooxygenase-2 inhibition and thromboxane A(2) receptor antagonism attenuate hypoxic pulmonary vasoconstriction in a porcine model.

Kylhammar D, Rådegran G.

Acta Physiol (Oxf). 2012 Aug;205(4):507-19. doi: 10.1111/j.1748-1716.2012.02437.x. Epub 2012 May 4.

PMID:
22554045
13.

Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model.

Wiklund A, Kylhammar D, Rådegran G.

J Cardiovasc Pharmacol. 2012 May;59(5):441-9. doi: 10.1097/FJC.0b013e31824938f0.

PMID:
22240915
14.

Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.

Hedelin P, Kylhammar D, Rådegran G.

Acta Physiol (Oxf). 2012 Mar;204(3):419-34. doi: 10.1111/j.1748-1716.2011.02339.x. Epub 2011 Aug 12.

PMID:
21726419

Supplemental Content

Loading ...
Support Center